1. Home
  2. CET vs MNMD Comparison

CET vs MNMD Comparison

Compare CET & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CET

Central Securities Corporation

HOLD

Current Price

$50.85

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Mind Medicine (MindMed) Inc.

MNMD

Mind Medicine (MindMed) Inc.

HOLD

Current Price

$13.43

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CET
MNMD
Founded
1929
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CET
MNMD
Price
$50.85
$13.43
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$30.33
AVG Volume (30 Days)
38.3K
2.0M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
4.54%
N/A
EPS Growth
N/A
N/A
EPS
7.40
N/A
Revenue
$27,062,484.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.85
N/A
Revenue Growth
15.78
N/A
52 Week Low
$40.24
$4.70
52 Week High
$52.44
$14.43

Technical Indicators

Market Signals
Indicator
CET
MNMD
Relative Strength Index (RSI) 53.32 57.40
Support Level $50.60 $12.85
Resistance Level $51.31 $13.54
Average True Range (ATR) 0.66 0.69
MACD 0.04 0.05
Stochastic Oscillator 58.90 62.94

Price Performance

Historical Comparison
CET
MNMD

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: